Karyopharm Therapeutics - SINE compound KPT-350

Karyopharm Therapeutics is a clinical-stage pharmaceutical company that treats several neurological and neurodegenerative conditions.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development and subsequent commercialization of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases It is headquartered in Newton, Mass., inked the deal with Biogen for its oral SINE compound KPT-350 and other assets to treat several neurological and neurodegenerative conditions. KPT-350 inhibits XP01, which reduces inflammation and neurotoxity while increasing neuroprotective responses. Although it has broader potential applications, the initial focus is on amyotrophic lateral sclerosis (ALS).